



Universitätsklinik für Nuklearmedizin
Direktor: Univ.-Prof. Dr. Irene J. Virgolini
Anichstrasse 35 · A – 6020 Innsbruck
Telefon +43 (0)50 504-22651
Telefax +43 (0)50 504-22659
nuklearmedizin@i-med.ac.at
<http://www.nuklearmedizin-innsbruck.com>

CURRICULUM VITAE AND SELECTED PUBLICATION LIST

Univ.-Prof. Dr. Irene Johanna VIRGOLINI



Born 29th December 1962 in Klagenfurt, Austria

Ordinary Professor of Nuclear Medicine
Director, Department of Nuclear Medicine
Medical University of Innsbruck
Anichstrasse 35
6020 Innsbruck, Austria

Phone: 0043-512-504-22650

Fax: 0043-512-504-22659

email: irene.virgolini@tirol-kliniken.at

<http://www.nuklearmedizin-innsbruck.com>

Irene Johanna Virgolini

Graduate Medical Education:

- 1981-1987 Medical education and degree (M.D.), University of Vienna
(Promotion Dr.med.univ., 23.6.1987)
- 1987-1991 II. Medizinische Universitätsklinik, University of Vienna
Garnisongasse 9, 1090 Vienna.
- 1991-2000 Department of Nuclear Medicine, University of Vienna,
General Hospital of Vienna (AKH), Währinger Gürtel 18-20.
- 1994 Specialist in Internal Medicine
- 1996 Specialist in Nuclear Medicine

Medical Positions:

- II/2000 – VIII/2004 Director, Institute of Nuclear Medicine, Vienna City
Hospital Lainz, 1130 Vienna.**
- since X/2003 Full Professor of Nuclear Medicine, Director of the
Department of Nuclear Medicine, Medical University of
Innsbruck (X/2003-II/2004 on leave)**

Scientific Carrier:

- 1984 Institute of Human Genetics, Section of Histopathology, (Univ.-Prof. W.
Schnedl), Schwarzspanierstrasse 17, University of Vienna.
- 1985 Department of Surgery A (Univ.-Prof. C. Chaimoff), Hasharon Hospital,
Sackler Medical School of the Tel Aviv University, Petah Tiquah, Israel.
- 1987 Approbation of the MD-thesis "Characterization of PGI₂-receptor binding sites
on normal and pathologically altered human thyroid tissue. Comparative
radioligand study with respect to clinical findings and the thyroid physiology".
- 1985-1991 Institute of Physiology, Atherosclerosis Research Group,
Schwarzspanierstrasse 17, University of Vienna.
- 1986-1991 Department of Nuclear Medicine ("Isotopenstation"), 2nd Department of
Medicine, General Hospital of Vienna, University of Vienna, Garnisongasse 9.
- 1992 *venia docendi* in "Experimental Nuclear Medicine" (University of Vienna,
^{99m}Tc-Neogalactoalbumin Scintigraphy for Liver Imaging).

Irene Johanna Virgolini

- 1992-2000 Head, Experimental Nuclear Medicine Research Group,
Department of Nuclear Medicine, General Hospital of University of Vienna.
- 1995 *venia docendi* in "Internal Medicine" (University of Vienna,
¹²³I-Vasoactive Intestinal Peptide Receptor Scintigraphy in Oncology)

Memberships/ Societies:

- 1985-1991 Atherosclerosis Research Group (ASF) Vienna
1986-1991 Austrian Society for Prostaglandin Research (APR)
since 1989 European Association of Nuclear Medicine (EANM)
1990-1993 International Society of Radiolabeled Blood Elements (ISORBE)
1990-1992 Kommission für Atherosclerose und Thromboseforschung
der Österreichischen Akademie der Wissenschaften (ATK)
1991-2007 Society of Nuclear Medicine (SNM)
since 2016 Society of Nuclear Medicine and Molecular Imaging (SNMMI)
1993-2000 Österreichische Gesellschaft für Innere Medizin
1993-1997 New York Academy of Sciences
since 1994 Österreichische Gesellschaft für Nuklearmedizin
1994-2000 European Society for Clinical Investigation (ESCI)
1996-2005 Österreichische Gesellschaft für Endokrinologie und Stoffwechsel
1998-2000 Verein zur Förderung der Wissenschaftlichen Forschung (Wien)
2008-2013 Society for Molecular Imaging
since 2008 World Assoc. of Radiopharmaceutical & Molecular Therapy (WARMTH)
since 2014 Österreichische Schilddrüsengesellschaft (OSDG)

Advisory Boards / Presidential Ships:

- 1997-2004 IAEA (International Atomic Energy Agency), Advisory Board Member
(IAEA permanent scientific staff member in 1999, Division of Nuclear
Medicine, Department of Human Health), Vienna International Center
2001-2005 Ludwig Boltzmann Institute of Experimental Oncology and
Photodynamic Therapy (President)
2002 WHO, Task Group Member for Oncology
2000-2006 EANM (European Association of Nuclear Medicine), Therapy Committee
Member, Alpine Task Group Member
2002-2006 Austrian Research Center Seibersdorf, Austria
since 2006 HopeXChange, Rome
2006-2012 EANM (Oncology Committee Member, Therapy Task Group Member)
2009-2010 Österreichischer Seniorenkrebshilfe Verein (Co-President)
2011 International Scientific Advisory Board of the European Institute of
Oncology, Milano, Italy
since 2012 WARMTH (World Association of Radiopharmaceutical and Molecular
Therapy), (Governmental Body since 2012), President-Elect (2016-
2017), President (2018-2019), Immediate Past President (2020-2022)

Irene Johanna Virgolini

Editorial Boards/ Reviewerships:

- 1990-1992 Thrombosis Research
1996-2010 The Journal of Nuclear Medicine and Molecular Imaging
since 1998 Pharmainformation
since 2002 Nuklearmedizin/Nuclear Medicine (Section Editor Molecular Therapy until 2019)
since 2002 The World Journal of Nuclear Medicine and Molecular Imaging
since 2003 The European Journal of Nuclear Medicine and Molecular Imaging
since 2006 Turkish Journal of Nuclear Medicine
since 2010 International Journal of Molecular Imaging
since 2010 Quarterly Journal of Nuclear Medicine (Guest Editor)
- since 1994 Permanent reviewer of all major journals of Nuclear Medicine and/or Molecular Imaging, committee member of various international journals

Publications:

>215 original publications, >95 proceedings, >30 reviews

Impact Factor: ~900 total (~250 first author, ~350 senior author, ~300 co-author)

Citation Index (1990-2020):~6.000; **Hirsch Index:** >40

(based on Web of Science: <http://isiknowledge.com>)

Selected Publications:

Liver function in acute viral hepatitis as determined by a hepatocyte-specific ligand: ^{99m}Tc-galactosyl-neoglycoalbumin. **Virgolini IJ**, Müller C, Höbart, J, Scheithauer, W, Angelberger P, Bergmann, O'Grady J, Sinzinger H. Hepatology. 1992 Apr;15(4):593-598.

Characterization of prostaglandin (PG)-binding sites expressed on human basophils. Evidence for a prostaglandin E1, I2, and a D2 receptor. **Virgolini IJ**, Li S, Sillaber C, Majdic O, Sinzinger H, Lechner K, Bettelheim P, Valent P. J Biol Chem. 1992 Jun 25;267(18):12700-12708.

Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. **Virgolini IJ**, Yang Q, Li S, Angelberger P, Neuhold N, Niederle B, Scheithauer W, Valent P. Cancer Res. 1994 Feb 1;54(3):690-700.

Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. **Virgolini IJ**, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P. New Engl J Med. 1994 Oct 27;331(17):1116-1121.

Vasoactive intestinal peptide receptor scintigraphy. **Virgolini IJ**, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B, Valent P. J Nucl Med. 1995 Oct;36(10):1732-1739.

Irene Johanna Virgolini

Image fusion analysis of ^{99m}Tc -HYNIC-Tyr³-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo , Kovacs P, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2005 Dec; 32(12):1440-1451.

Comparison of ^{111}In -DOTA-DPhe¹-Tyr³-octreotide and ^{111}In -DOTA-*lanreo*-tide scintigraphy and dosimetry in patients with neuroendocrine tumours. Rodrigues M, Traub-Weidinger T, Li S, Ibi B, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2006 May; 33(5):532-540.

^{99m}Tc -depreotide scintigraphy versus ^{18}F -FDG-PET in the diagnosis of radioiodine-negative thyroid cancer. Rodrigues M, Li S, Gabriel M, Heute D, Greifeneder M, **Virgolini IJ**. J Clin Endocrinol Metab. 2006 Oct;91(10):3997-4000.

^{68}Ga -DOTA-Tyr³-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, **Virgolini IJ**. J Nucl Med. 2007 Apr;48(4):508-518.

Concordance between results of somatostatin receptor scintigraphy with ^{111}In -DOTA-DPhe¹-Tyr³-octreotide and chromogranin. An assay in patients with neuroendocrine tumours. Rodrigues M, Gabriel M, Heute D, Putzer D, Griesmacher A, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2008 Oct; 35(10): 1796-1802.

Bone metastases in patients with neuroendocrine tumor: ^{68}Ga -DOTA-Tyr³-octreotide PET in comparison to CT and bone scintigraphy. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, Decristoforo C, Bale RJ, Jaschke W, **Virgolini IJ**. J Nucl Med. 2009 Aug;50(8):1214-1221.

^{68}Ga -DOTA-Tyr³-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, Uprimny C, Kovacs P, Bale R, **Virgolini IJ**. J Nucl Med. 2009 Sep;50(9):1427-1434.

Procedure guidelines for PET/CT tumour imaging with ^{68}Ga -DOTA-conjugated peptides: ^{68}Ga -DOTA-TOC, ^{68}Ga -DOTA-NOC, ^{68}Ga -DOTA-TATE. **Virgolini IJ**, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, De Cristoforo C, Chiti A. Eur J Nucl Med Mol Imaging. 2010 Oct; 37(10): 2004-2010.

Diagnosis and therapy are walking together on radiopeptides' avenue. Mansi L, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2011 Apr; 38(4):605-612.

Functional imaging in pheochromocytoma and neuroblastoma with ^{68}Ga -DOTA-Tyr³-octreotide positron emission tomography and ^{123}I -metaiodobenzylguanidine. Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, Kranewitter C, Warwitz B, Waitz D, Kendler D, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2011 May; 38(5):865-873.

^{99m}Tc -Demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study. Gabriel M, Decristoforo C, Wöll E, Eisterer W, Nock B, Maina T, Moncayo R, **Virgolini IJ**. Cancer Biother Radio. 2011 Oct;26(5):557-563.

Irene Johanna Virgolini

First experience with proteasome inhibitor treatment of radioiodine nonavid thyroid cancer using bortezomib. Putzer D, Gabriel M, Kroiss A, Madleitner R, Eisterer W, Kendler D, Uprimny C, Bale RJ, Gastl G, **Virgolini IJ**. Clin Nucl Med. 2012 Jun;37(6):539-544

Somatostatin receptor PET in neuroendocrine tumours: ^{68}Ga -DOTA⁰,Tyr³-octreotide versus ^{68}Ga -DOTA⁰-lanreotide. Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, von Guggenberg E, Decristoforo C, Warwitz B, Widmann G, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2013 Feb; 40(3):364-372.

^{68}Ga -DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, Gabriel M, Kendler D, Waitz D, Widmann G, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2013 Apr; 40(4):514-523.

Design and Evaluation of Novel Radiolabelled VIP Derivatives for Tumour Targeting. Rangger C, Helbok A, Ocak M, Radolf T, Andreae F, **Virgolini IJ**, von Guggenberg E, Decristoforo C. Anticancer Res. 2013 Apr;33(4):1537-1546

Development of ^{68}Ga -labelled DTPA galactosyl human serum albumin for liver function imaging. Haubner R, Vera DR, Farshchi-Heydari S, Helbok A, Rangger C, Putzer D, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1245-1255.

A retrospective comparison between ^{68}Ga -DOTA-TOC PET/CT and ^{18}F -DOPA PET/CT in patients with extra-adrenal paraganglioma. Kroiss A, Putzer D, Frech A, Decristoforo C, Uprimny C, Gasser RW, Shulkin BL, Url C, Widmann G, Prommegger R, Sprinzl GM, Fraedrich G, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1800-8.

Nuclear Medicine 2013: from status quo to status go. Beyer T, Hacker M, Schubiger A, **Virgolini IJ**, Wester H. Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1794-1796.

Somatostatin receptor PET in neuroendocrine tumours: ^{68}Ga -DOTA⁰,Tyr³-octreotide versus ^{68}Ga -DOTA⁰-lanreotide. Putzer D., Kroiss A., Waitz D., Gabriel M., Traub-Weidinger T., Uprimny C., Von Guggenberg E., Decristoforo C., Warwitz B., Widmann G., **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2013;40:364-72.

^{68}Ga -DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to ^{123}I -MIBG SPECT/CT. Kroiss A, Shulkin BL, Uprimny C, Frech A, Gasser RW, Url C, Gautsch K, Madleitner R, Nilica B, Sprinzl GM, Gastl G, Fraedrich G, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):33-41.

Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme. Gamper EM, Wintner LM, Rodrigues M, Buxbaum S, Nilica B, Singer S, Giesinger JM, Holzner B, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1179-88.

^{68}Ga -PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1284-94.

Irene Johanna Virgolini

Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Traub-Weidinger T, Putzer D, von Guggenberg E, Dobrozemsky G, Nilica B, Kendler D, Bale R, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1995-2001.

Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? (Editorial) **Virgolini IJ**, Innsbruck Team. European Journal of Nuclear Medicine and Molecular Imaging. Clin Genitourin Cancer. 2015 Dec;13(6):e415-7.

Therapie des Patienten mit Radioiod-refraktärem, differenziertem Schilddrüsenkarzinom. Ein Konsensusstatement.] Lindner C., Dierneder J., Pall G., Pirich C., Hoffmann M., Raderer M., Becherer A., Niederle B., Lipp R., Lind P., Gallowitsch H., Romeder F., **Virgolini IJ**. Nuklearmedizin. 2015;54:125-30.

Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? **Virgolini IJ**; Innsbruck Team. Eur J Nucl Med Mol Imaging. 2015 Dec;42(13):1949-54.

Direct comparison of ⁶⁸Ga-DOTA-TOC and ¹⁸F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, **Virgolini IJ**, Rodrigues M. Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1585-92.

⁶⁸Ga-NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis. Haubner R, Finkenstedt A, Stegmayr A, Rangger C, Decristoforo C, Zoller H, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):2005-13.

Current knowledge on the sensitivity of the ⁶⁸Ga-somatostatin receptor positron emission tomography and the SUV_{max} reference range for management of pancreatic neuroendocrine tumours. **Virgolini IJ**, Gabriel M, Kroiss A, von Guggenberg E, Prommegger R, Warwitz B, Nilica B, Roig LG, Rodrigues M, Uprimny C. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):2072-83.

A Delphic Consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumour disease management. Oberg KE, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke MH, Pavel M, Cwikla JB, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, **Virgolini IJ**, Kjaer A, Modlin I. Endocr Connect. 2016 Sep;5(5):174-87.

Early dynamic imaging in ⁶⁸Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, Roig LG, Kendler D, von Guggenberg E, Bektic J, Horninger W, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2017 May;44(5):765-775.

Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation. Joensuu T, Joensuu G, Kairemo K, Kiljunen T, Riener M, Aaltonen A, Ala-Opas M,

Irene Johanna Virgolini

Kangasmäki A, Alanko T, Taipale L, Hervonen P, Bützow A, **Virgolini IJ**, Hemminki A. *Anticancer Res.* 2016 Dec;36(12):6439-6447.

The $^{68}\text{Ga}/^{177}\text{Lu}$ theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV_{max} values and absorbed dose estimates. Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, Decristoforo C, Uprimny C, Lukas P, Horninger W, **Virgolini IJ**. *Eur J Nucl Med Mol Imaging.* 2017 May;44(5):788-800.

^{68}Ga -PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, **Virgolini IJ**. *Eur J Nucl Med Mol Imaging.* 2017 Jun;44(6):941-949.

^{68}Ga -NOTA-Galactosyl Human Serum Albumin: a Tracer for Liver Function Imaging with Improved Stability. Haubner R, Schmid AM, Maurer A, Rangger C, Roig LG, Pichler BJ, **Virgolini IJ**. *Mol Imaging Biol.* 2017 Oct;19(5):723-730.

Evaluation of Noncompletion Bias and Long-Term Adherence in a 10-Year Patient-Reported Outcome Monitoring Program in Clinical Routine. Gamper EM, Nerich V, Sztankay M, Martini C, Giesinger JM, Scarpa L, Buxbaum S, Jeller M, Holzner B, **Virgolini IJ**. *Value Health.* 2017 Apr;20(4):610-617.

Development of standardized image interpretation for ^{68}Ga -PSMA PET/CT to detect prostate cancer recurrent lesions. Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, Hofman MS, Eiber M, Schwarzenbock S, Castellucci P, Bellisario C, Chauvie S, Bergesio F, Emmett L, Haberkorn U, **Virgolini IJ**, Schwaiger M, Hicks RJ, Krause BJ, Chiti A. *Eur J Nucl Med Mol Imaging.* 2017 Sep;44(10):1622-1635.

Early PET imaging with ^{68}Ga -PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. Uprimny C, Kroiss AS, Fritz J, Decristoforo C, Kendler D, von Guggenberg E, Nilica B, Maffey-Steffan J, di Santo G, Bektic J, Horninger W, **Virgolini IJ**. *Eur J Nucl Med Mol Imaging.* 2017 Sep;44(10):1647-1655.

Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with ^{68}Ga -DOTA-conjugated somatostatin receptor targeting peptides and ^{18}F -DOPA. Bozkurt MF, **Virgolini IJ**, Balogova S, Beheshti M, Rubello D, Decristoforo C, Ambrosini V, Kjaer A, Delgado-Bolton R, Kunikowska J, Oyen WJG, Chiti A, Giammarile F, Sundin A, Fanti S. *Eur J Nucl Med Mol Imaging.* 2017 Nov;44(12):2150-2151.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Re: Silke Gillissen, Gerhardt Attard, Tomasz M. Beer, et al. *Eur Urol.* In press. <http://dx.doi.org/10.1016/j.eururo.2017.06.002>. von Eyben FE, **Virgolini IJ**, Roviello G. *Eur Urol.* 2017 Aug 28. pii: S0302-2838(17)30696-6.

Current status of theranostics in prostate cancer. **Virgolini IJ**, Decristoforo C, Haug A, Fanti S, Uprimny C. *Eur J Nucl Med Mol Imaging.* 2018 Mar;45(3):471-495.

Comparison of ^{68}Ga -PSMA-11 PET/CT with ^{18}F -NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. Uprimny C,

Irene Johanna Virgolini

Svirydenka A, Fritz J, Kroiss AS, Nilica B, Decristoforo C, Haubner R, von Guggenberg E, Buxbaum S, Horninger W, **Virgolini IJ**. Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1873-1883.

Quality of life in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy: information from a monitoring program in clinical routine. Martini C, Buxbaum S, Rodrigues M, Nilica B, Scarpa L, Holzner B, **Virgolini IJ**, Gamper EM. J Nucl Med. 2018 Oct;59(10):1566-1573.

Twelve-year Follow-up after Peptide Receptor Radionuclide Therapy (PRRT). Gabriel M, Nilica B, Kaiser B, **Virgolini IJ**. J Nucl Med. 2019 Apr;60(4):524-529.

The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma. Dizdarevic S, Tulchinsky M, McCready VR, Mihailovic J, Vinjamuri S, Buscombe JR, Lee ST, Frangos S, Sathekge M, Siraj Q, Choudhury P, Bom H, Franceschi M, Ugrinska A, Paez D, Hussain R, Mailman J, Luster M, **Virgolini IJ**; WARMTH Thyroid Group. World J Nucl Med. 2019 Apr-Jun;18(2):123-126.

The $^{68}\text{Ga}/^{177}\text{Lu}$ -theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. Maffey-Steffan J, Scarpa L, Svirydenka A, Bernhard N, Mair C, Buxbaum S, Bektic J, von Guggenberg E, Uprimny C, Horninger W, **Virgolini I**. Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):740.

EANM procedure guidelines for radionuclide therapy with ^{177}Lu -labelled PSMA-ligands (^{177}Lu -PSMA-RLT). Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, **Virgolini I**, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. Eur J Nucl Med Mol Imaging. 2019;46:2536-2544.

^{68}Ga -DOTATOC PET/CT in the localization of head and neck paraganglioma compared with ^{18}F -DOPA PET/CT and ^{123}I -MIBG SPECT/CT. Kroiss AS, Uprimny C, Shulkin BL, Gruber L, Frech A, Url C, Riechelmann H, Sprinzl GM, Thomé C, Treglia G, Kjaer A, Fraedrich G, **Virgolini IJ**. Nucl Med Biol. 2019 Apr;71:47-53.

Prior Therapies as Prognostic Factors of Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With [^{177}Lu]Lu-PSMA-617. A WARMTH Multicenter Study (The 617 Trial). Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, Kulkarni HR, Zhang J, Gerke C, Fimmers R, Kratochwil C, Rathke H, Ilhan H, Maffey-Steffan J, Sathekge M, Kabasakal L, Garcia-Perez FO, Kairemo K, Maharaj M, Paez D, **Virgolini I**. Eur J Nucl Med Mol Imaging. 2020 May 8. Doi: 10.1007/s00259-020-04797-9-Online ahead of print.

Consensus on Molecular Imaging and Theranostics in Neuroendocrine Tumours. Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, De Herder W, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, O'Toole D, Pavel M, Ruzsniowski P, Scarpa A, Strosberg J, Sundin A, Täieb D, **Virgolini I**, Wild D, Herrmann K, Yao J. To be submitted in Lancet Oncology.

Invited Lectures at International Meetings

Since 1986 **>300 invited lectures** (including many plenary lectures) held at International Congresses, Universities, Faculties, worldwide, on the topics of molecular imaging and/or therapy with peptide radiopharmaceuticals.

Patents:

Patent 1997, Wiener Patentamt: „**Trägersubstanz für Radionuklide zur Diagnose und / oder Zerstörung von Tumorgewebe**“. Inhaber: Irene Virgolini (Inventors: P.Smith-Jones, P. Angelberger, Irene Virgolini). (A451/97 Priority).

Patent 1998 - EU-Patent (PCR application / AT 98/00065): „**Radiomarkierte Somatostatin Rezeptor-Liganden zur Diagnose und Therapie**“ Inhaber: Nycomed-Amersham, Irene Virgolini, P. Smith-Jones und P. Angelberger (Inventors: P. Smith-Jones, P. Angelberger, Irene Virgolini).

Scientific Awards (>Over 30 national and international awards) including:

- 1992 **Jean Debieesse Award** ("Lipoprotein Receptor Imaging") presented at the European Association of Nuclear Medicine (EANM Annual Congress), Lissabon, Portugal.
- 1992 **Award of the International Union of Angiology** ("Evidence for increased monocyte uptake in patients with heterocygous familial hypercholesterolemia in vivo"), presented at the World Congress on Angiology, Paris, France.
- 1994 **Jean Debieesse Award** ("VIP Receptor Imaging") presented at the European Association of Nuclear Medicine (EANM Annual Congress), Düsseldorf, Germany.
- 1996 **Martin-Gülzow Award** ("VIP Receptor Imaging") presented at the Annual Congress of the German Society of Gastrointestinal Diseases, Aachen, Germany.
- 1996 **Editorial Board Award of the Journal of Nuclear Medicine** for the best clinical paper of the year 1995, presented at the Annual Congress of the Society of Nuclear Medicine (SNM), Denver, USA.
- 1997 **Mac Forster Award** "Receptor Nuclear Medicine: VIP and somatostatin receptor scintigraphy for diagnosis and treatment of tumor patients" (Nomination by the European Society of Clinical Investigation), Kiel, Germany Meeting.
- 2008 **Editorial Board Award of the Journal of Nuclear Medicine** for the best clinical paper of the year 2007, presented at the Annual Congress of the Society of Nuclear Medicine (SNM), New Orleans, USA.
- 2008 **Alavi-Mandell Award 2008** presented by the Society of Nuclear Medicine (SNM), New Orleans, USA, for "⁶⁸Ga-DOTA-Tyr³-octreotide PET imaging in neuroendocrine tumours" (The Journal of Nuclear Medicine 2007; 48: 508-518).
- 2010 **Alavi-Mandell Award 2010** presented by the Society of Nuclear Medicine (SNM), Salt Lake City, USA, for "⁶⁸Ga-DOTA-Tyr³-octreotide PET imaging for response assessment of somatostatin-receptor-mediated radionuclide therapy" (J Nucl Med. 2009; 50: 1427-1434).
- 2012 **EANM-Springer-Preis** for the "Best Basic Science Paper 2011" presented at the Annual Congress of the EANM, Milan, Italy, ⁶⁸Ga-NODAGA-RGD for imaging *avβ3*

Irene Johanna Virgolini

- integrin expression. (Eur J Nucl Med Mol Imaging. 2011 Jul; 38(7): 1303-1312 and Eur J Nucl Med Mol Imaging. 2013 Aug;40(8):1245-1255).
- 2018 **Förderungspreis Nuklearmedizin (2017)** at the OGNMB, presented at the Annual Meeting of the OGNMB, Zell am See, for „⁶⁸Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour“. (Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949).
- 2018 **Rudolf-Höfer-Preis (OGNMB) 2018** presented on the Billrothhaus, Vienna, Austria for the publication „Early PET imaging with ⁶⁸Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence“. (Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1647-1655).
- 2018 **EANM-Springer-Preis** for the “Best Paper 2018” presented on the Annual Congress of the EANM, Düsseldorf, Germany for “⁶⁸Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour“. (Eur J Nucl Med Mol Imaging 2017 Jun;44(6):941-949).
- 2019 **Preis der Ärztekammer für Tirol 2018** “The ⁶⁸Ga/¹⁷⁷Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUV_{max} values and absorbed dose estimates.” Eur J Nucl Med Mol Imaging. 2017 May;44(5):788-800.
- 2020 **Ilse-Zoller-Förderungspreis für Naturwissenschaften (OGNMB) 2020**, presented at the „14. Nationaler OGNMB Kongress“, Zell am See, January 21-23, 2021 „DOTA-MGS5, a New Cholecystinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.“ J Nucl Med. 2019 Jul;60(7):1010-1016.

University Academic Positions:

- Member of the Academic Senate, MUI (since 2006)
- Member of the Habilitation Commission, MUI (since 2006)
- Member of the Academic Award Commission, MUI (since 2006)
- Member of the Council of the Medical University of Vienna (2019)

Innsbruck, July 2020

Univ.-Prof. Dr. Irene Johanna Virgolini